Alligator CEO provides snapshot of tumor-directed IO pipeline

Following a deal, worth potentially $700m plus, signed in 2015 with Johnson & Johnson’s Janssen Biotech, Swedish biotech Alligator Biosciences AB is well placed to drive its clinical pipeline. During Biotech Showcase, CEO Per Norlén outlined to Scrip the current status of the pipeline and its plans moving forward which includes having five clinical programs in place by the end of 2019.
With programs designed for tumor-directed immunotherapy, focusing on immunostimulatory receptors that can provide long-lasting protection against cancer, Swedish biotech Alligator Biosciences, according to CEO Per Norlén, has enough money to enable it to progress five clinical programs to Phase II proof of concept. That is its inflexion point at which it ideally will seek pharma partners to further develop the programs.